Almost a year has elapsed since the beginning of the current revival of interest in the sulfonylureas as hypoglycemic agents. The first announcements, made in the German medical press in October, 1955,1 were quickly relayed to other countries, including Canada and the United States. Intensive study is being conducted here and the sale of the drugs is being postponed pending substantial proof of safety in prolonged use, mechanisms of action, and clear indications for therapy. Two pharmaceutical firms are supplying their products, now known as carbutamide (BZ-55) and tolbutamide (Orinase, U-2043), to clinical investigators who are observing their action in many laboratories and in several thousand diabetic subjects.
Three conferences have been held during 1956 ( two in Indianapolis and one in Kalamazoo ) in which leading researchers in the United States and Canada have reported current data and debated their significance. Symposiums on the subject have been or will be
Colwell AR, Ingle D, Krahl ME, Levine R, Ricketts HT. PROGRESS REPORT OF AMERICAN DIABETES ASSOCIATION ON ORALLY EFFECTIVE HYPOGLYCEMIC SULFONYLUREASGUEST EDITORIAL. JAMA. 1956;162(10):976–977. doi:10.1001/jama.1956.02970270036012
Customize your JAMA Network experience by selecting one or more topics from the list below.